ACTG175

ACTG 175 was a randomized clinical trial to compare monotherapy with zidovudine or didanosine with 
combination therapy with zidovudine and didanosine or zidovudine and zalcitabine in adults infected with the human 
immunodeficiency virus type I whose CD4 T cell counts were between 200 and 500 per cubic millimeter.

datasets

The package performs estimation and testing of the
        treatment effect in a 2-group randomized clinical trial with a
        quantitative, dichotomous, or right-censored time-to-event
        endpoint. The method improves efficiency by leveraging baseline
        predictors of the endpoint. The inverse probability weighting
        technique of Robins, Rotnitzky, and Zhao (JASA, 1994) is used
        to provide unbiased estimation when the endpoint is missing at
        random.

ACTG175: AIDS Clinical Trials Group Study 175

Description

Usage

Arguments

Details

References